FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

Thumbnail
View
Author
Cho, Byoung Chul ORCID
Goto, Koichi ORCID
Johnson, Melissa ORCID
Garon, Edward ORCID
FELIP, ENRIQUETA ORCID
Spira, Alexander ORCID
Date
2025-01
Permanent link
http://hdl.handle.net/11351/12749
DOI
10.1016/j.lungcan.2024.108066
ISSN
0169-5002
WOS
001398449200001
PMID
39764938
Share on TwitterShare on FacebookShare on TelegramShare on WhatsappShare on Linkedin

Show full item record
Keywords
Firmonertinib; Furmonertinib; Metastatic
Bibliographic citation
Spira A, Cho BC, Felip E, Garon EB, Goto K, Johnson M, et al. FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004). Lung Cancer. 2025 Jan;199:108066.
Audience
Professionals
This item appears in following collections

The following license files are associated with this item: